[1] |
Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158.
|
[2] |
陈孝平, 张志伟. 肝癌多学科综合治疗团队建立与运作[J]. 中国实用外科杂志, 2014, 34(8): 685-687.
|
[3] |
中华人民共和国卫生部. 原发性肝癌诊疗规范(2019年版)[J]. 中国临床医学, 2020, 27(1): 140-160.
|
[4] |
Cho YB, Lee KU, Lee HW, et al. Outcomes of hepatic resection fora single large hepatocellular carcinoma[J]. World J Surg, 2007, 31(4): 795-801.
|
[5] |
Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: risk factors,screening and clinical presentation[J]. World J Hepatol, 2019, 11(3): 261-272.
|
[6] |
Feng K, Yan J, Li X, et al. A randomized controlled trial of radio frequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]. J Hepatol, 2012, 57(4): 794-802.
|
[7] |
Zhou C, Peng Y, Zhou K, et al. Surgical resection plus radio frequency ablation for the treatment of multifocal hepatocellular carcinoma[J]. Hepatobiliary Surg Nutr, 2019, 8(1): 19-28.
|
[8] |
沈锋, 王葵, 薛辉, 等. 肝癌行肝切除术和肝移植的合理选择[J]. 中国实用外科杂志, 2018, 38(2): 121-125.
|
[9] |
Honjo I, Suzuki T, Ozawa K, et al. Ligation of a branch of the portal vein for carcinoma of the liver[J]. Am J Surg, 1975, 130(3): 296-302.
|
[10] |
Guiu B, Chevallier P, Denys A, et al. Simultaneous trans-hepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique[J]. Eur Radiol, 2016, 26(12): 4259-4267.
|
[11] |
文天夫. 转化切除是提高肝细胞癌切除率的重要途径[J]. 中国普外基础与临床杂志, 2020, 28(2): 133-135.
|
[12] |
Panaro F, Giannone F, Riviere B, et al. Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center[J]. Hepatobiliary Surg Nutr, 2019, 8(4): 329-337.
|
[13] |
Guiu B, Quenet F, Escal L, et al. Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function[J]. Eur Radiol, 2017, 27(8): 3343-3352.
|
[14] |
Robles R, Parrilla P, López-Conesa A, et al. Tourniquet modification of the associating liver partition and portal ligation for staged hepatectomy procedure[J]. Br J Surg, 2014, 101(9): 1129-1134.
|
[15] |
Raptis DA, Linecker M, Kambakamba P, et al. Defining Benchmark Outcomes for ALPPS[J]. Ann Surg, 2019, 270(5): 835-841.
|
[16] |
Kim D, Cornman-Homonoff J, Madoff DC. Preparing for liver surgery with "Alphabet Soup": PVE, ALPPS, TAE-PVE, LVD and RL[J]. Hepatobiliary Surg Nutr, 2020, 9(2): 136-151.
|
[17] |
Deshayes E, Schadde E, Piron L, et al. Extended liver venous deprivation leads to a higher increase in liver function that ALPPS in early assessment : A comment to "Sparrelid,E. et al. Dynamic Evaluation of Liver Volume and Function in Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy. Journal of Gastrointestinal Surgery (2017)"[J]. J Gastrointest Surg, 2017, 21(10): 1754-1755.
|
[18] |
李川江, 周杰. 肝细胞肝癌经肝动脉化疗栓塞联合索拉非尼降期后二期切除的初步报告[J]. 腹部外科, 2017, 30(4): 295-298, 301.
|
[19] |
Tustumi F, Ernani L, Coelho FF, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: A systematic review and Meta-analysis[J]. HPB (Oxford), 2018, 20(12): 1109-1118.
|
[20] |
Ronot M, Cauchy F, Gregoli B, et al. Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden[J]. HPB (Oxford), 2016, 18(8): 684-690.
|
[21] |
Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69(8): 1492-1501.
|
[22] |
Ettorre GM, Laurenzi A, Vennarecci G. Downstaging Hepatocellular Carcinoma with Yttrium-90 radioembolization: resection or transplantation?[J]. Eur J Surg Oncol, 2014, 40(6): 789-790.
|
[23] |
Labgaa I, Tabrizian P, Titano J, et al. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma[J].HPB(Oxford), 2019, 21(11): 1497-1504.
|
[24] |
Tabone M, Calvo A, Viganò L, et al. Downstaging to liver resection by radioembolization: A difficult to reach strategy?[J]. Eur J Surg Oncol, 2013, 39(8): 918-919.
|
[25] |
Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization[J]. Am J Transplant, 2009, 9(8): 1920-1928.
|
[26] |
He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: A prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83.
|
[27] |
He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960.
|
[28] |
鲁俊玲, 王冰洁, 张佳光. 肝脏储备功能评估方法及临床意义[J]. 海南医学, 2019, 30(8): 1058-1061.
|
[29] |
陆华泽, 王小波, 黎乐群. 原发性肝癌术前肝储备功能评估方法的研究进展[J]. 中国普通外科杂志, 2020, 29(1): 85-96.
|
[30] |
方驰华, 卢绮萍, 刘允怡. 复杂性肝脏肿瘤三维可视化精准诊治指南(2019版)[J]. 中国实用外科杂志, 2019, 39(8): 766-774.
|
[31] |
Yang J, Tao HS, Cai W, et al. Accuracy of actual resected liver volume in anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imaging[J]. J Surg Oncol, 2018, 118(7): 1081-1087.
|
[32] |
Hanna GB, Shimi SM, Cuschieri A, et al. Randomised study of influence of two-dimensional versus three-dimensional imaging on performance of laparoscopic cholecystectomy[J]. Lancet, 1998, 351(9098): 248-251.
|
[33] |
中华医学会外科学分会腹腔镜与内镜外科学组, 中国医师协会外科医师分会微创外科医师委员会. 3D腹腔镜手术技术中国专家共识(2019版)[J]. 中国实用外科杂志, 2019, 39(11): 1136-1141.
|
[34] |
刘荣, 尹注增, 赵之明, 等. 应用机器人手术系统行肝胆胰手术单中心1 000例报告[J]. 中国实用外科杂志, 2017, 37(3): 288-290.
|